Jyong Biotech Ltd. Ordinary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MENS research report →
Price Chart
About the company
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace.
- CEO
- Fu-Feng Kuo
- IPO
- 2025
- Employees
- 27
- HQ
- New Taipei City, TP, TW
Get TickerSpark's AI analysis on MENS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $110.24M
- P/E
- -16.76
- PEG
- 0.35
- P/S
- 0.00
- P/B
- -4.32
- EV/EBITDA
- -48.58
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 19.39%
- ROIC
- 46.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-100,000+16.7%
- Op Income
- $-2,607,000
- Net Income
- $-4,671,000-54.7%
- EPS
- $-0.06-61.2%
- OCF Growth
- +16.1%
- FCF Growth
- +16.1%
- 52W High
- $38.88
- 52W Low
- $1.43
- 50D MA
- $1.95
- 200D MA
- $2.08
- Beta
- 2.52
- RSI (14)
- 45
- Avg Volume
- 43.09K
No earnings-call transcripts are available for MENS yet.
- Free Float
- 36.9%
- Shares Outstanding
- 76.03M
- Float Shares
- 28.06M
of shares held by institutions
19 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 284.12K | ▲ 23.81K |
| Geode Capital Management, LLC | 73.41K | ▲ 4.53K |
| Xtx Topco Ltd | 29.07K | ▲ 29.07K |
| Citigroup Inc | 21.23K | ▲ 18.73K |
| Stonex Group Inc. | 15.25K | ▲ 15.25K |
| China Universal Asset Management Co., Ltd. | 13.87K | ▲ 1.77K |
| Barclays PLC | 6.91K | ▲ 976 |
| Morgan Stanley | 6.13K | ▲ 16 |
| Jpmorgan Chase & Co | 5.04K | ▼ 344 |
| Mirae Asset Global Investments Co., Ltd. | 3.88K | ▲ 485 |
| Bnp Paribas Financial Markets | 3.10K | ▲ 390 |
| Gf Fund Management Co. Ltd. | 1.70K | ▲ 138 |
Held by 18 ETFs
Biggest fund positions in MENS by dollar value.
Our MENS coverage
Recent articles, reports, and earnings notes.
No research on MENS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MENS report →Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California
globenewswire.com · Oct 21
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
globenewswire.com · Oct 15
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
globenewswire.com · Sep 3
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
globenewswire.com · Jul 23
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
globenewswire.com · Jul 23
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
globenewswire.com · Jul 2
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
globenewswire.com · May 29
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
globenewswire.com · May 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.